Progyny, Inc. Provides Earnings Outlook for the Third Quarter and Full Year 2022
August 04, 2022 at 05:09 pm EDT
Share
Progyny, Inc. provided earnings outlook for the Third Quarter and Full Year 2022. For the Quarter, the company's Revenue is projected to be $190.0 million to $197.0 million, reflecting growth of 55% to 61%. Net income is projected to be $1.9 million to $3.3 million, or $0.02 to $0.03 per diluted share, on the basis of approximately 102 million assumed weighted-average fully diluted-shares outstanding.
For the Year, the company's Revenue is now projected to be $750.0 million to $775.0 million, reflecting growth of 50% to 55%. Net income is projected to be $13.8 million to $19.5 million, or $0.14 to $0.19 per diluted share, on the basis of approximately 102 million assumed weighted-average fully diluted-shares outstanding.
Progyny, Inc. is a benefit management company. The Company specializes in fertility and family building benefits solutions in the United States. The Companyâs clients include various employers across an array of industries. It has contracts to provide coverage to approximately 6.4 million employees and their partners (known as members). The Company provides its benefits through its proprietary Smart Cycle approach. Smart Cycles include the medical services required for a memberâs full course of treatment, including all necessary diagnostic testing and access to the technology. In addition to its fertility benefits solution, the Company offers an integrated pharmacy benefits solution, Progyny Rx, which can be added by its clients. Progyny Rx provides its members with access to the medications needed during their fertility treatment. It provides care management services, as well as medication administration training, pharmacy support services and continuing patient care advocate support.
PROGYNY, INC. 
